Last reviewed · How we verify
AON-D21
AON-D21 is a small molecule that targets the PI3K/AKT/mTOR pathway.
AON-D21 is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Metastatic triple-negative breast cancer.
At a glance
| Generic name | AON-D21 |
|---|---|
| Sponsor | Aptarion Biotech AG |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AON-D21 works by inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT/mTOR pathway, which is involved in cell growth and survival. This inhibition leads to a decrease in the activity of AKT and mTOR, resulting in anti-tumor effects.
Approved indications
- Metastatic triple-negative breast cancer
Common side effects
- Hyperglycemia
Key clinical trials
- Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. (PHASE2)
- Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects. (PHASE1)
- First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AON-D21 CI brief — competitive landscape report
- AON-D21 updates RSS · CI watch RSS
- Aptarion Biotech AG portfolio CI